These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26250653)

  • 1. P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain.
    Choi JY; Song JS; Lee M; Cho WK; Chung J; Lyoo CH; Kim CH; Park J; Lee KC; Kim KM; Kang JH; Bae MA; Ryu YH
    Mol Imaging Biol; 2016 Apr; 18(2):267-73. PubMed ID: 26250653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
    Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
    Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
    Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
    Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
    Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
    Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar.
    la Fougère C; Böning G; Bartmann H; Wängler B; Nowak S; Just T; Wagner E; Winter P; Rominger A; Förster S; Gildehaus FJ; Rosa-Neto P; Minuzzi L; Bartenstein P; Potschka H; Cumming P
    Neuroimage; 2010 Jan; 49(2):1406-15. PubMed ID: 19796699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
    Dörner B; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Müllauer J; Bauer F; Mairinger S; Löscher W; Miller DW; Chiba P; Müller M; Erker T; Langer O
    Bioorg Med Chem; 2011 Apr; 19(7):2190-8. PubMed ID: 21419632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
    Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
    J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
    Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
    Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
    Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
    Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of limiting brain penetration of probes for α(2C)-adrenoceptor using small-animal positron emission tomography.
    Kawamura K; Akiyama M; Yui J; Yamasaki T; Hatori A; Kumata K; Wakizaka H; Takei M; Nengaki N; Yanamoto K; Fukumura T; Zhang MR
    ACS Chem Neurosci; 2010 Jul; 1(7):520-8. PubMed ID: 22778842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
    Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
    Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies.
    Piel M; Schmitt U; Bausbacher N; Buchholz HG; Gründer G; Hiemke C; Rösch F
    Neuropharmacology; 2014 Sep; 84():152-8. PubMed ID: 23994301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans.
    Mukherjee J; Bajwa AK; Wooten DW; Hillmer AT; Pan ML; Pandey SK; Saigal N; Christian BT
    J Comp Neurol; 2016 May; 524(7):1457-71. PubMed ID: 26509362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective microPET imaging of brain 5-HT(1A) receptors in rats with [(18) F]MeFWAY by suppression of radioligand defluorination.
    Choi JY; Kim CH; Jeon TJ; Kim BS; Yi CH; Woo KS; Seo YB; Han SJ; Kim KM; Yi DI; Lee M; Kim DG; Kim JY; Lee KC; Choi TH; An G; Ryu YH
    Synapse; 2012 Dec; 66(12):1015-23. PubMed ID: 22927318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice.
    Kawamura K; Yamasaki T; Konno F; Yui J; Hatori A; Yanamoto K; Wakizaka H; Takei M; Kimura Y; Fukumura T; Zhang MR
    Mol Imaging Biol; 2011 Feb; 13(1):152-60. PubMed ID: 20379788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
    Ganguly S; Panetta JC; Roberts JK; Schuetz EG
    Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.